GPCR therapeutic monoclonal antibodies  · 11. September 2021

SYnAbs unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR and C5aR GPCR. Functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.

Membrane functional antibodies : depleting, blocking, neutralizing, agonist and antagonist · 21. August 2021

SYnAbs generates innovative functional monoclonals against clusters of differentiation markers, IgG superfamily, and C-type lectin-like receptors (CLRs). Discover how SYnAbs generate Siplizumab anti-human CD2 antibody and other transmembrane effector monoclonals.

GPCR therapeutic monoclonal antibodies  · 30. June 2021

SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to modified peptides, DNA and cell immunization strategies

Membrane functional antibodies : depleting, blocking, neutralizing, agonist and antagonist · 09. April 2021

To address all B cell depletion needs, SYnAbs has developed monoclonal antibody references, which exhibit the ability to deplete murine or rat B cells in vivo, providing a valuable research tool for its biotech and pharma partners.

Monoclonal antibody targeting virus envelope · 08. March 2021

How to generate effective neutralizing antibodies to target infectious disease transmembrane protein antigens. A review of the technical challenges, strategies, and risks.